Olanzapine
Brand Names: Zyprexa
Methodology & AI Transparency ⓘ
Olanzapine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia.
- 2 Real-world patient consensus: 76% patient "Worth It" rating across 9 anonymous logs for Olanzapine (RxNorm 312076).
- 3 Typical cash cost range: Dispensing cost comparison spans $6.21 mail/discount cash up to $34.50 uninsured retail (federal NADAC $0.1069).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Olanzapine: headache (10.8%), dizziness (6.5%), fatigue (6.3%).
Ask our AI Specialists anything about Olanzapine
Olanzapine Mechanism, CYP450 Pathways & DailyMed Monograph
Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. (1.1) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. (14.1) Adolescents (ages 13 to 17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) . The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents.
12.1 Mechanism of Action The mechanism of action of olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.
With Depot mucosal/cutaneous persistence without significant systemic accumulation of Olanzapine residence kinetics and < 5% transdermal or mucosal systemic uptake from Olanzapine bioavailability, Olanzapine undergoes local esterase/enzymatic cleavage of olanzapine with minimal hepatic cytochrome burden and establishes therapeutic activity over initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (olanzapine).
Standard adult regimens span 5 mg/1 Tablet, 5 mg/1 Tablet, Film Coated, 15 mg/1 Tablet, 10 mg/1 Tablet, Film Coated, 2.5 mg/1 Tablet. Prescribers screen specifically against none with olanzapine orally disintegrating tablets monotherapy.; when using olanzapine orally disintegrating tablets and fluoxetine in combination, also refer to the contraindications section of the package insert for symbyax., while community micro-logs most frequently note headache (10.8% of reports), constipation (6.7% of reports), dizziness (6.5% of reports).
Enzyme inducers accelerate biotransformation of Olanzapine, potentially lowering trough levels below therapeutic threshold.
Avoid overlapping atypical antipsychotic prescriptions alongside Olanzapine to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- None with olanzapine orally disintegrating tablets monotherapy.
- When using olanzapine orally disintegrating tablets and fluoxetine in combination, also refer to the Contraindications section of the package insert for Symbyax.
Logged Side-Effect Incidence (9 Reports)
Olanzapine Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Olanzapine)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic: What a 259-Participant Study Found The incidence of TD was relatively low in both younger and older patients with depression with psychotic features treated acutely with olanzapine. Journal of clinical psychopharmacology • 2013-06-15 • Randomized Controlled Trial | N = 259 | 93/100 | PMID 23609383 ↗ |
| New Insights on Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of: What a 281-Participant Study Found Conclusion: In this 56-week post hoc analysis of patients initially experiencing an acute exacerbation of schizophrenia, OLZ/SAM was associated with significant and durable improvement in negative symptoms of schizophrenia,... The Journal of clinical psychiatry • 2026-03-09 • Phase III Randomized Trial | N = 281 | 93/100 | PMID 41944743 ↗ |
| New Insights on Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced: What a 690-Participant Study Found This trial did not provide sufficient evidence to support that deletion of the NK-1 receptor antagonist was as good as keeping it, as a part of a 4-drug antiemetic regimen for highly emetogenic chemotherapy. The oncologist • 2023-08-03 • Phase III Randomized Trial | N = 690 | 93/100 | PMID 37284847 ↗ |
| Can This Approach Help? Inside the Latest Research on Central nervous system symptom burden and clinical implications for antiemetic CNS symptom burden was associated with suboptimal CINV control, while 5 mg of olanzapine maintained superior antiemetic efficacy across CNS symptom strata. The oncologist • 2026-09-09 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42714265 ↗ |
| Can This Approach Help? Inside the Latest Research on Olanzapine combined with standard antiemetics for the prevention of nausea and Conclusion This trial provides the first high-level evidence supporting the olanzapine-based four-drug combination to prevent CINV in GCT patients undergoing 5-day cisplatin-based chemotherapy. European journal of cancer (Oxford, England : 1990) • 2025-06-03 • Phase III Randomized Trial | N = 77 | 88/100 | PMID 40311506 ↗ |
Olanzapine Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1069/unit (~$3.21/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $6.21 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 9 Anonymous DotMD Community Micro-Logs | $7.50 / mo | View logs ↓ |
Olanzapine Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Olanzapine RxNorm Concept ID | 312076 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1069 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $6.21 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 76.00% Worth It (9 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Olanzapine Patient Community, Cohort Filters & Dosage Logs
Cross-verified Olanzapine (atypical antipsychotic) monograph synthesizing RxNorm 312076, openFDA FAERS signals, and $6.21–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Olanzapine community threads and patient logs by age, biological sex, dosage, and treatment duration.